Amlodipine/valsartan/rosuvastatin (CJ-30060) vs OLOMAX
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: Angiotensin II receptor / Calcium channel / HMG-CoA reductase · full Hypertension pipeline
Amlodipine/valsartan/rosuvastatin (CJ-30060)
Developed by HK inno.N Corporation
NCT03536598 · Phase 3 · completed
The trial randomly assigned 203 participants and used quadruple blinding with two active comparator groups. Its primary endpoints were changes in LDL-C and sitting systolic blood pressure at 8 weeks, but no results or statistical comparisons are posted, so the primary endpoint cannot be judged as met or missed.
No aligned efficacy figure on record for this race.
OLOMAX
Marketed by Daewoong Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Hypertension
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Amlodipine/valsartan/rosuvastatin (CJ-30060) | OLOMAX |
|---|---|---|
| Seated SBP, change | —Not posted · NCT03536598 | —Not reported |
| 24-hour ambulatory SBP, change | —Not posted · NCT03536598 | —Not reported |
| Seated DBP, change | —Not posted · NCT03536598 | —Not reported |
Seated SBP, change
- Amlodipine/valsartan/rosuvastatin (CJ-30060)
- —Not posted · NCT03536598
- OLOMAX
- —Not reported
24-hour ambulatory SBP, change
- Amlodipine/valsartan/rosuvastatin (CJ-30060)
- —Not posted · NCT03536598
- OLOMAX
- —Not reported
Seated DBP, change
- Amlodipine/valsartan/rosuvastatin (CJ-30060)
- —Not posted · NCT03536598
- OLOMAX
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Amlodipine/valsartan/rosuvastatin (CJ-30060): no structured comparison results are available for Hypertension.
OLOMAX: no structured comparison results are available for Hypertension.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Amlodipine/valsartan/rosuvastatin (CJ-30060)'s landscape · OLOMAX's landscape